Brief: Canbridge Pharmaceuticals Says Granted Orphan Drug Designation For CAN 106 For Treatment Of Myasthenia Gravis By The U.S. FDA
16/11/2022 01:07
Nov 15 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* CANBRIDGE PHARMACEUTICALS INC- GRANTED ORPHAN DRUG
DESIGNATION
FOR CAN 106 FOR TREATMENT OF MYASTHENIA GRAVIS BY THE U.S. FDA
Source text for Eikon: ID:nBw2wPtrra
Further company coverage: 1228.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares